本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

Jaguar Animal Health, Inc.

2.14
+0.04001.90%
盤後2.140.00000.00%19:18 EDT
成交量:5.01萬
成交額:10.68萬
市值:409.69萬
市盈率:-0.02
高:2.20
開:2.10
低:2.02
收:2.10
52周最高:35.25
52周最低:1.93
股本:191.44萬
流通股本:178.03萬
量比:0.99
換手率:2.81%
股息:- -
股息率:- -
每股收益(TTM):-130.6878
每股收益(LYR):-130.6878
淨資產收益率:-459.52%
總資產收益率:-37.48%
市淨率:2.30
市盈率(LYR):-0.02

資料載入中...

公司資料

公司名字:
Jaguar Animal Health, Inc.
交易所:
NASDAQ
成立時間:
- -
員工人數:
49
公司地址:
200 Pine Street,Suite 400,San Francisco,California,United States
郵編:
94104
電話:
傳真:
- -
簡介:
Jaguar Health, Inc.於2013年6月6日在特拉華州成立。該公司是一家商業階段的製藥公司,專註於為患有胃腸道(“GI”)疾病的人和動物開發可持續地從雨林地區的植物中提取的新型專利處方藥。

董事

名稱
職位
James J. Bochnowski
Chairman of the Board
Lisa A. Conte
Chief Executive Officer, President and Director
Anula Jayasuriya
Director
John Micek III
Director
Jonathan B. Siegel
Director

股東

名稱
職位
Lisa A. Conte
Chief Executive Officer, President and Director
Carol R. Lizak
Chief Financial Officer
Jonathan S. Wolin
Chief of Staff, General Counsel and Chief Compliance Officer
Pravin Chaturvedi
Chief Scientific Officer
Steven R. King
Chief of Sustainable Supply, Ethnobotanical Research and Intellectual Property and Secretary